Cinclus Pharma

18.18 SEK

-1.09 %

Less than 1K followers

CINPHA

NASDAQ Stockholm

Biotechnology & Pharmaceuticals

Health Care

Overview

Financials & Estimates

Ownership

Investor consensus

-1.09 %

+3.30 %

+6.94 %

-2.26 %

-14.97 %

-18.05 %

-

-

-44.24 %

Cinclus Pharma is a Swedish pharmaceutical company in the clinical phase. The company is active in the development of molecules for the treatment of acid-related diseases. The company's leading drug candidate linaprazan glurate is being developed for the treatment of severe gastroesophageal reflux disease (GERD). Cinclus Pharma was founded in 2014 and has its headquarters in Stockholm.

Market cap

861.59M SEK

Turnover

866.01K SEK

Revenue

4.58M

EBIT %

-3,703.93 %

P/E

-

Dividend yield-%

-

Revenue and EBIT-%

Revenue M

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Financial calendar

19/1

2026

Extraordinary general meeting '26

18/2

2026

Annual report '25

13/5

2026

Interim report Q1'26

All

Webcasts

Press releases

ShowingAll content types

Regulatory press release12/8/2025, 7:00 AM

Cinclus Pharmas linaprazan glurate har inkluderats på Kinas nationella ersättningslista och lanseras i Kina 2026

Regulatory press release12/8/2025, 7:00 AM

Cinclus Pharma’s linaprazan glurate earns China’s National Reimbursement Listing and is set to launch in China in 2026

Regulatory press release12/8/2025, 6:30 AM

Cinclus Pharma rekryterar Magnus Christensen som ny CFO

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account

Followings and notifications on followed companies

Analyst comments and recommendations

Stock comparison tool & other popular tools

Regulatory press release12/8/2025, 6:30 AM

Cinclus Pharma recruits Magnus Christensen as new CFO

Regulatory press release12/8/2025, 6:00 AM

Kallelse till extra bolagsstämma i Cinclus Pharma Holding AB (publ)

Regulatory press release12/8/2025, 6:00 AM

Notice of Extraordinary General Meeting in Cinclus Pharma Holding AB (publ)

Regulatory press release12/1/2025, 2:25 PM

Cinclus Pharmas valberedning föreslår ny representant för bolagets grundare till styrelsen

Regulatory press release12/1/2025, 2:25 PM

Cinclus Pharma’s Nomination Committee proposes new representative for the company’s founders to the Board

Press release11/26/2025, 7:00 AM

Cinclus Pharma bjuder in till KOL-event: insikter om klinisk praxis för patienter med erosiv gatroesofageal refluxsjukdom (GERD)

Press release11/26/2025, 7:00 AM

Cinclus Pharma invites to KOL event: insights on clinical practice for erosive Gastroesophageal Reflux Disease (GERD) patients

Press release11/20/2025, 2:19 PM

Redeye: Cinclus Pharma (Q3 review) - Pivotal studies underway

Cinclus Pharma, Audiocast, Q3'25

Webcast11/20/2025, 9:00 AM

Cinclus Pharma, Audiocast, Q3'25

Regulatory press release11/20/2025, 7:00 AM

En positiv inledning av fas III-studien

Regulatory press release11/20/2025, 7:00 AM

A positive start to the Phase III study

Regulatory press release11/20/2025, 7:00 AM

En positiv inledning av fas III-studien

Regulatory press release11/20/2025, 7:00 AM

A positive start to the Phase III study

Regulatory press release11/18/2025, 7:00 AM

Cinclus Pharma's Nomination Committee for the 2026 Annual General Meeting appointed

Regulatory press release11/18/2025, 7:00 AM

Cinclus Pharmas Valberedning för årsstämma 2026 utsedd

Press release11/10/2025, 7:00 AM

Cinclus Pharma sponsrar vetenskapligt abstract till konferens som belyser de kliniska och ekonomiska kostnaderna av misslyckade behandlingar med PPI vid svår erosiv GERD

Press release11/10/2025, 7:00 AM

Cinclus Pharma sponsors a scientific conference abstract highlighting the significant clinical and economic costs of PPI treatment failures in severe erosive GERD

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.